CN117204560A - Functional food for resisting uric acid - Google Patents
Functional food for resisting uric acid Download PDFInfo
- Publication number
- CN117204560A CN117204560A CN202311312601.1A CN202311312601A CN117204560A CN 117204560 A CN117204560 A CN 117204560A CN 202311312601 A CN202311312601 A CN 202311312601A CN 117204560 A CN117204560 A CN 117204560A
- Authority
- CN
- China
- Prior art keywords
- parts
- uric acid
- functional food
- gout
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940116269 uric acid Drugs 0.000 title claims abstract description 35
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 32
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 235000013376 functional food Nutrition 0.000 title claims abstract description 18
- 210000000582 semen Anatomy 0.000 claims abstract description 7
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 5
- 241000628997 Flos Species 0.000 claims abstract 2
- 244000111489 Gardenia augusta Species 0.000 claims description 13
- 240000005373 Panax quinquefolius Species 0.000 claims description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 12
- 244000197580 Poria cocos Species 0.000 claims description 12
- 235000008599 Poria cocos Nutrition 0.000 claims description 12
- 240000007164 Salvia officinalis Species 0.000 claims description 10
- 235000004426 flaxseed Nutrition 0.000 claims description 9
- 235000005412 red sage Nutrition 0.000 claims description 9
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 claims description 8
- 241000282376 Panthera tigris Species 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 7
- 241001116742 Drynaria Species 0.000 claims description 5
- 235000018958 Gardenia augusta Nutrition 0.000 claims description 5
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 4
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 4
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 4
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 4
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 4
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 4
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 4
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 4
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 4
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 4
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 4
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 4
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 4
- 229940107666 astragalus root Drugs 0.000 claims description 4
- 241000205585 Aquilegia canadensis Species 0.000 claims 1
- 240000000171 Crataegus monogyna Species 0.000 claims 1
- 244000182216 Mimusops elengi Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 38
- 201000005569 Gout Diseases 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 18
- 231100000331 toxic Toxicity 0.000 abstract description 10
- 230000002588 toxic effect Effects 0.000 abstract description 10
- 239000008187 granular material Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000029142 excretion Effects 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 3
- 210000004185 liver Anatomy 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 208000035240 Disease Resistance Diseases 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 235000013361 beverage Nutrition 0.000 abstract description 2
- 230000003907 kidney function Effects 0.000 abstract description 2
- 230000003908 liver function Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 241001122767 Theaceae Species 0.000 description 13
- 235000013616 tea Nutrition 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 229940126673 western medicines Drugs 0.000 description 9
- 241000723343 Cichorium Species 0.000 description 8
- 235000007542 Cichorium intybus Nutrition 0.000 description 8
- 241001570521 Lonicera periclymenum Species 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 229960001338 colchicine Drugs 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 7
- 229960003081 probenecid Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000007774 longterm Effects 0.000 description 6
- 239000009636 Huang Qi Substances 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 229940126680 traditional chinese medicines Drugs 0.000 description 5
- 241000045403 Astragalus propinquus Species 0.000 description 4
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 4
- 235000006533 astragalus Nutrition 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 244000037364 Cinnamomum aromaticum Species 0.000 description 3
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 3
- 241001092040 Crataegus Species 0.000 description 3
- 201000001431 Hyperuricemia Diseases 0.000 description 3
- 241000234435 Lilium Species 0.000 description 3
- 240000002624 Mespilus germanica Species 0.000 description 3
- 240000000249 Morus alba Species 0.000 description 3
- 235000008708 Morus alba Nutrition 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 244000046146 Pueraria lobata Species 0.000 description 3
- 235000010575 Pueraria lobata Nutrition 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 241000657480 Crataegus pinnatifida Species 0.000 description 2
- 241001148783 Davallia mariesii Species 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 240000006240 Linum usitatissimum Species 0.000 description 2
- 235000004431 Linum usitatissimum Nutrition 0.000 description 2
- 241000245240 Lonicera Species 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- 235000001188 Peltandra virginica Nutrition 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 description 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 229930183118 Tanshinone Natural products 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 206010019847 hepatosplenomegaly Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 201000003265 lymphadenitis Diseases 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000015091 medicinal tea Nutrition 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 201000004409 schistosomiasis Diseases 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241001149932 Archaeognatha Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241001480537 Fomitopsis Species 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001506371 Kadsura Species 0.000 description 1
- 241000561705 Kadsura coccinea Species 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 240000009022 Smilax rotundifolia Species 0.000 description 1
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 1
- 206010041290 Soft tissue inflammation Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241001619444 Wolfiporia cocos Species 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 231100000850 chronic interstitial nephritis Toxicity 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical class [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/30—Mashed or comminuted products, e.g. pulp, pastes, meal, powders; Products made therefrom, e.g. blocks, flakes, snacks; Liquid or semi-liquid products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a functional food, namely an anti-uric acid functional food. The functional food is prepared from Poria, flos Lonicerae, caulis Kadsurae Longipedunculatae, and semen Lini by making into beverage, tablet or instant granule. The beneficial effects are that: the functional food can enhance uric acid excretion function of human body, has quick effect, no toxic or side effect, can quickly relieve or even eliminate gout symptoms, can provide various nutritional ingredients for human body, improve liver and kidney functions, improve disease resistance of human body, has auxiliary treatment effect on patients with high uric acid and gout, has good synergistic effect on various existing medicines, has soft taste, is convenient to eat, has low cost, and is expected to become a preferred dietotherapy product for people with high uric acid and patients with gout.
Description
Technical Field
The invention relates to a functional food, namely an anti-uric acid functional food.
Background
Gout is an inflammatory disease induced by monosodium urate crystals, and can lead to hyperuricemia through long-term purine metabolism activity, excessive purine intake or uric acid excretion disorder. Long-term hyperuricemia can cause urate crystal deposition in joints and surrounding soft tissues, and repeated attacks of acute joint and soft tissue inflammation, tophus deposition, chronic arthritis and joint damage occur. Hyperuricemia can also involve the kidneys, causing chronic interstitial nephritis and urate calculi formation. Early positive uric acid lowering treatment for gout patients can delay or prevent organ damage. Currently, the treatment of gout is mainly drug treatment, including western medicines, traditional Chinese medicines and dietotherapy. Western medicines such as non-steroidal anti-inflammatory drugs, colchicine, glucocorticoid and the like adopted in the acute stage. In the chronic stage, uric acid reducing medicines such as allopurinol, febuxostat, benzbromarone and probenecid are mainly adopted, so that the effect is quick, the toxic and side effects are strong, and the medicine is not suitable for long-term use. Traditional Chinese medicines are various, but have slow effect, hardly act on acute onset of gout, have bad taste, are painful to take, have toxic and side effects, and cannot be taken for a long time. The food therapy adopts national approved medicine and food homologous materials, has no toxic or side effect and strong palatability, and is expected to replace partial medicine treatment. In particular to some medicinal tea drinks, such as the well-known chicory gardenia tea and the like, which can supplement water and urine, promote uric acid excretion and have good mouthfeel, so the medicinal tea drink is suitable for long-term administration. However, the existing dietotherapy products have the problem of slow effect, even slower than traditional Chinese medicines, thereby limiting the application of dietotherapy. If the dietotherapy can accelerate the development process of the dietotherapy, the dietotherapy becomes a main means for resisting gout, thereby bringing good news to gout patients and even the whole society.
Disclosure of Invention
The invention aims to provide a dietotherapy product which can enhance uric acid excretion function of human body, has quick response, convenient use, low cost and no toxic or side effect.
The above purpose is realized by the following technical scheme: providing an anti-uric acid functional food, which is characterized in that: 6-8 parts of poria cocos, 2-5 parts of honeysuckle, 2-6 parts of black tiger and 2-4 parts of flaxseed.
The raw materials are added: 1-3 parts of gardenia jasminoides ellis, 1-3 parts of red sage root, 2-4 parts of hawthorn and 1-3 parts of drynaria rhizome.
The raw materials are added: 0.1-0.5 part of American ginseng, 0.5-1 part of red sage root, 0.5-1 part of astragalus root, 1-3 parts of medlar and 1-3 parts of drynaria rhizome.
The beneficial effects of the invention are as follows: the prepared functional food can enhance uric acid excretion function of human body, has quick response, no toxic or side effect, can quickly relieve gout symptoms, can provide various nutrients for human body, improve liver and kidney functions and microcirculation level, greatly improve disease resistance of human body, has synergistic effect on various existing related medicines, has soft taste, is convenient to eat, has low cost, and is expected to become a preferred dietary therapy product for high uric acid crowd and gout patients.
Description of the embodiments
First embodiment: provides a functional food with anti-uric acid effect on gout, which is characterized in that: the functional food is prepared from 6-8 parts of poria cocos, 2-5 parts of honeysuckle, 2-6 parts of black tiger and 2-4 parts of flaxseed.
Poria, the academic name Wolfiporia cocos, also known as Yuling, fuling, mo Linggui, fu Tu. Is dry sclerotium of Poria cocos (Roxb.) wolf of Fomitopsis. The main component of the tuckahoe is tuckahoe glycan, which has inhibition effect on various bacteria; can reduce gastric acid, has obvious protective effect on digestive tract ulcer and liver injury, and has anti-tumor effect; can regulate immune function in multiple ways; can accelerate leucopenia and return caused by chemotherapy; and has sedative effect. Poria is the key herb for promoting diuresis and removing dampness, and is used for treating symptoms such as difficult urination, stagnation of water and dampness, edema and the like, and has special effects no matter the poria is biased to cold and dampness or biased to damp-heat, and mild medicine property and promoting diuresis without damaging vital qi. Poria cocos and rhizoma smilacis glabrae are two different raw materials, but the poria cocos and rhizoma smilacis glabrae show different ideas in the process of treating gout.
Honeysuckle, also called honeysuckle (academic name: lonicera japonica), is a good herb for clearing heat and detoxicating, which is a dried flower bud or a flower with a primary bloom of the lonicera plant of the lonicera. It has sweet and cold nature, fragrant Gan Hanqing heat without hurting stomach, fragrant and penetrating effect, can dispel wind-heat, and can also clear away blood-toxin, and is used for treating various febrile diseases such as fever, eruption, spot, sore and abscess due to heat toxin, and sore throat. The Chinese medicinal composition can supplement the effect of resisting adverse qi and killing by being matched with Poria cocos, so that the Chinese medicinal composition can be replaced by rhizoma smilacis glabrae.
Black tiger (academic name: kadsura coccinea (lem)) a.c. Smith (alias), cold rice roll, smelly rice roll, wine rice roll, cross mountain dragon vine, diamond, majoram, georgi, purple root vine, xiaoxiao, red cross mountain, bristletail, and large She Na five flavors, are plants of the magnoliaceae Kadsura genus. The ripe fruits are sweet and edible. Its root and fruit can be used as medicine. For this example, the root active ingredient is higher and the amount is smaller. The fruit can be used fresh or made into powder, and the dosage after the powder preparation can be equivalent to the root to be replaced by 1.5 times of the dosage of the root.
Flaxseed (Linseed, segment lini) is a mature seed of dicotyledonous flax. Also known as semen Sesami, semen autumn, semen Cannabis, and semen Lini. Is rich in essential fatty acid of Omega-3, and has effects of improving skin, caring skin, reducing weight, resisting anaphylaxis, preventing and treating arthritis and multiple organ tissue inflammation, relieving asthma, improving blood pressure, reducing blood lipid, reducing blood viscosity, preventing blood coagulation, and preventing apoplexy and heart disease.
The administration method is preferably tea. 15-20 g of the tea is infused into 500ml of tea for adults each time, and the tea is taken 3-5 times a day.
The study procedure of the above formula is briefly described: in clinic, gout is mainly treated by medicines, including western medicines, traditional Chinese medicines and dietotherapy. The western medicine has quick response, can relieve pain in 1-2 days, but has strong toxic and side effects, is not suitable for long-term use, and cannot radically cure. The traditional Chinese medicine can inhibit the cause of disease, but has slow effect, poor taste and toxic and side effects, and is not suitable for long-term administration. The dietotherapy has good taste and no toxic or side effect, but has the defect of slow effect. The gout is relatively acute in onset and difficult in pain, and particularly a dietetic product with high effect taking speed is needed. In 2013-2015, through the arrangement study of the medical records of the past year, the effective time of the formula is obviously faster than that of the food therapy formula of the same kind, and the formula has important clinical significance although the formula is slower than western medicines.
The medical records data arrangement method comprises the following steps: the number of cases of males is 90, (the cases of males are adopted because gout is mostly male), and the cases are divided into three groups, namely an experimental group, a control group 1 and a control group 2, and 30 cases of each group. The experimental group adopts medicinal granules prepared by the formula, and the control group 1 adopts chicory gardenia tea which is a commercially available product, wherein the formula comprises chicory, mulberry leaves, kudzuvine root, gardenia, lily and cassia seeds. The control group 2 is western medicines colchicine and probenecid, the colchicine is used in the acute stage, and the probenecid is used in the chronic stage. According to the current standard, the male adult has a uric acid level of 300-350 mu mol/L which is a normal value, and the patient with a blood uric acid level of 420 mu mol/L or more is consciously ill, and the clinical patient has a blood uric acid level of about 500 mu mol/L. The time from the start of the administration to the pain relief and the start of the decrease of uric acid level is the effective time. The time from the administration to the stabilization of uric acid level below 420. Mu. Mol/L, and the substantial disappearance of pain is the relief time.
The statistical results are shown in the following table:
the statistics can be seen as follows: the effective time and the buffer time of the formula are equal to those of the commercially available chicory gardenia tea. Although the prescription has longer effective time than western medicines, the prescription has shorter release time than western medicines, has stable effect, no toxic or side effect, good taste and convenient drinking, and is favored by patients.
Second embodiment: further improvements are made on the basis of the foregoing embodiments. Adding fructus Gardeniae, saviae Miltiorrhizae radix, fructus crataegi and rhizoma Drynariae into the formula to form a new formula: 6-8 parts of poria cocos, 2-5 parts of honeysuckle, 2-6 parts of black tiger, 2-4 parts of flaxseed, 1-3 parts of fructus gardeniae, 1-3 parts of radix salviae miltiorrhizae, 2-4 parts of hawthorn and 1-3 parts of rhizoma drynariae. Preferably 7 parts of glabrous greenbrier rhizome, 3 parts of honeysuckle, 4 parts of black tiger, 3 parts of flaxseed, 2 parts of gardenia jasminoides ellis, 2 parts of red sage root, 3 parts of hawthorn and 2 parts of rhizoma drynariae.
Fructus Gardeniae, alias: fructus Gardeniae (school name: gardenia jasminoides Ellis), also known as fructus Gardeniae, and Bufonis venenum, is fruit of Gardenia jasminoides Ellis of Rubiaceae, is traditional Chinese medicine, and has effects of protecting liver, promoting bile flow, lowering blood pressure, tranquilizing, stopping bleeding, and relieving swelling. The Chinese medicine is used for treating icteric hepatitis, sprain and contusion, hypertension, diabetes and other diseases in clinic, and belongs to the first medicine and food dual-purpose resource issued by the ministry of health.
Red sage root, (academic name: salvia miltiorrhiza Bunge): the dicotyledon Labiatae sage perennial upright herb is used as a seed root medicament, contains tanshinone, is a tonic menstruation-promoting agent, has the effects of removing blood stasis, promoting tissue regeneration, promoting blood circulation, regulating menstruation and the like, and has good effect on treating coronary heart disease. In addition, it can be used for treating neurasthenia, insomnia, arthralgia, anemia, mastitis, lymphadenitis, arthritis, sore, furuncle, swelling, erysipelas, acute and chronic hepatitis, renal Meng Shenyan, traumatic injury, late schistosomiasis hepatosplenomegaly, and epilepsy . It can be used for external application to treat sores.
Fructus crataegi is dried mature fruit of Crataegus pinnatifida Crataegus pinnatiida Bge.var.major N.E.Br. or Crataegus pinnatifida Crataegus pinnatifida Bge. Has effects of promoting digestion, resolving food stagnation, activating qi-flowing and removing blood stasis. Is mainly used for treating food stagnation, diarrhea and abdominal pain, hernia pain, chest and abdominal pain due to blood stasis, dysmenorrhea and the like.
Rhizoma Drynariae (academic name: davallia mariesii Moore ex Bak.) is an epiphyte of the genus Drynanthaceae, and has effects of strengthening bones and tonifying kidney.
The following processing technique is preferred: pulverizing fructus Gardeniae and Saviae Miltiorrhizae radix respectively, soaking in 50% Chinese liquor for 20-24 hr, respectively breaking wall of semen Lini, fructus crataegi and rhizoma Drynariae, grinding, processing other materials by conventional method, mixing, and making into beverage, tablet or instant granule.
The administration method comprises the following steps: tea is taken for 3-5 times daily after being infused with 500-600 ml tea after 20-25 g for adult each time.
The medical records data arrangement method comprises the following steps: the number of cases of males is 90, (the cases of males are adopted because gout is mostly male), and the cases are divided into three groups, namely an experimental group, a control group 1 and a control group 2, and 30 cases of each group. The experimental group adopts medicinal granules prepared by the formula, and the control group 1 adopts chicory gardenia tea which is a commercially available product, wherein the formula comprises chicory, mulberry leaves, kudzuvine root, gardenia, lily and cassia seeds. The control group 2 is western medicines colchicine and probenecid, the colchicine is used in the acute stage, and the probenecid is used in the chronic stage. According to the current standard, the male adult has a uric acid level of 300-350 mu mol/L which is a normal value, and the patient with a blood uric acid level of 420 mu mol/L or more is consciously ill, and the clinical patient has a blood uric acid level of about 500 mu mol/L. The time from the start of the administration to the pain relief and the start of the decrease of uric acid level is the effective time. The time from the administration to the stabilization of uric acid level below 420. Mu. Mol/L, and the substantial disappearance of pain is the relief time.
The statistical comparison results are shown in the following table:
therefore, the effect of the formula is better because the effective time of the formula is further shortened on the basis of the formula of the first embodiment.
Third embodiment: the improvement on the first embodiment. American ginseng, red sage root, astragalus root, wolfberry fruit and drynaria are added into the prescription. Forming a new formula: 6-8 parts of poria cocos, 2-5 parts of honeysuckle, 2-6 parts of black tiger, 2-4 parts of flaxseed, 0.1-0.5 part of American ginseng, 0.5-1 part of red sage root, 0.5-1 part of astragalus root, 1-3 parts of medlar and 1-3 parts of rhizoma drynariae. Preferably: 7 parts of poria cocos, 3 parts of honeysuckle, 4 parts of black tiger, 2 parts of flaxseed, 0.3 part of American ginseng, 0.8 part of red-rooted salvia root, 0.8 part of astragalus membranaceus, 2 parts of medlar and 2 parts of rhizoma drynariae.
The added raw materials are processed according to a conventional method, and finally the medicinal granules are prepared.
The administration method comprises the following steps: tea is taken for 3-5 times daily after being infused with 500-600 ml tea after 20-25 g for adult each time.
American ginseng (academic name: panax quinquefolius) isAraliaceae (Araliaceae)Ginseng is a perennial herb, aliasesFlower pattern Ginseng of American ginseng、American ginsengAmerican ginseng and American ginseng, can tonify qi and nourish yin,clearing heat and promoting fluid production. Is used for treating qi deficiency and yin deficiency, internal heat, cough and asthma, phlegm blood, dysphoria due to deficiency heat,diabetes mellitusDry mouth and throat, etc. The administration method comprises decocting, stewing, steaming, slicing, pulverizing into fine powder, and taking with water.
Red sage root, (academic name: salvia miltiorrhiza Bunge): the dicotyledon Labiatae sage perennial upright herb is used as a seed root medicament, contains tanshinone, is a tonic menstruation-promoting agent, has the effects of removing blood stasis, promoting tissue regeneration, promoting blood circulation, regulating menstruation and the like, and has good effect on treating coronary heart disease. In addition, it can be used for treating neurasthenia, insomnia, arthralgia, anemia, mastitis, lymphadenitis, arthritis, sore, furuncle, swelling, erysipelas, acute and chronic hepatitis, renal Meng Shenyan, traumatic injury, late schistosomiasis hepatosplenomegaly, and epilepsy . It can be used for external application to treat sores.
Radix astragali, latin's name Astragalus membranaceus (Fisch.) Bunge, namely radix astragali, also known as radix astragali, radix astragali with capsule, herba astragali with one person, radix astragali, is root of Astragalus mongholicus bge or Astragalus membranaceus bge. Because of its abundance in north China, it is one of the common traditional Chinese medicines.
FRUCTUS Lycii, FRUCTUS LYCII, isSolanaceae (Solanaceae)Mature fruit of Lycium barbarum. Fructus Lycii has various health promotion effects, and is a food approved by Ministry of health for both medicine and food.
Rhizoma Drynariae (academic name: davallia mariesii Moore ex Bak.) is an epiphyte of the genus Drynanthaceae, and has effects of strengthening bones and tonifying kidney.
The prescription is suitable for patients with deficiency of qi and blood and deep weakness, and has the effects of relieving pain and strengthening body.
The medical records data arrangement method comprises the following steps: the number of cases of males is 90, (the cases of males are adopted because gout is mostly male), and the cases are divided into three groups, namely an experimental group, a control group 1 and a control group 2, and 30 cases of each group. The experimental group adopts medicinal granules prepared by the formula, and the control group 1 adopts chicory gardenia tea which is a commercially available product, wherein the formula comprises chicory, mulberry leaves, kudzuvine root, gardenia, lily and cassia seeds. The control group 2 is western medicines colchicine and probenecid, the colchicine is used in the acute stage, and the probenecid is used in the chronic stage. According to the current standard, the male adult has a uric acid level of 300-350 mu mol/L which is a normal value, and the patient with a blood uric acid level of 420 mu mol/L or more is consciously ill, and the clinical patient has a blood uric acid level of about 500 mu mol/L. The time from the start of the administration to the pain relief and the start of the decrease of uric acid level is the effective time. The time from the administration to the stabilization of uric acid level below 420. Mu. Mol/L, and the substantial disappearance of pain is the relief time.
The statistical comparison results are shown in the following table:
in the table, the data show that the improved formula has greatly shortened effect and better effect compared with the control group.
Claims (4)
1. An anti-uric acid functional food, characterized in that: the functional food comprises Poria, flos Lonicerae, caulis Kadsurae Longipedunculatae and semen Lini.
2. The uric acid resistant functional food according to claim 1, wherein: the functional food comprises the following raw materials in parts by weight: 6-8 parts of poria cocos, 2-5 parts of honeysuckle, 2-6 parts of black tiger and 2-4 parts of flaxseed.
3. The uric acid resistant functional food according to claim 2, wherein: the raw materials are added with 1-3 parts of gardenia jasminoides ellis, 1-3 parts of red sage root, 2-4 parts of hawthorn and 1-3 parts of drynaria rhizome.
4. The uric acid resistant functional food according to claim 2, wherein: the raw materials are added with 0.1 to 0.5 part of American ginseng, 0.5 to 1 part of red sage root, 0.5 to 1 part of astragalus root, 1 to 3 parts of medlar and 1 to 3 parts of drynaria rhizome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311312601.1A CN117204560A (en) | 2021-03-04 | 2021-03-04 | Functional food for resisting uric acid |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110237415.0A CN113812614A (en) | 2021-03-04 | 2021-03-04 | Uric acid resistant functional food |
| CN202311312601.1A CN117204560A (en) | 2021-03-04 | 2021-03-04 | Functional food for resisting uric acid |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110237415.0A Division CN113812614A (en) | 2021-03-04 | 2021-03-04 | Uric acid resistant functional food |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117204560A true CN117204560A (en) | 2023-12-12 |
Family
ID=78912392
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110237415.0A Pending CN113812614A (en) | 2021-03-04 | 2021-03-04 | Uric acid resistant functional food |
| CN202311312601.1A Pending CN117204560A (en) | 2021-03-04 | 2021-03-04 | Functional food for resisting uric acid |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110237415.0A Pending CN113812614A (en) | 2021-03-04 | 2021-03-04 | Uric acid resistant functional food |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN113812614A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114747766A (en) * | 2022-04-27 | 2022-07-15 | 上海诚明圣源生物科技有限公司 | Health-care food composition capable of reducing uric acid and preparation method and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100381121C (en) * | 2005-03-30 | 2008-04-16 | 李健 | New use of linolenic acid in preparation of anti arthrolithiasis medicine or health care food |
| CN103875418B (en) * | 2014-03-26 | 2015-01-07 | 西藏自治区藏医院 | Method for producing comospore veronica sara-banda |
| CN107854634A (en) * | 2017-12-07 | 2018-03-30 | 珠海霍普金斯医药研究院股份有限公司 | A kind of fermented tcm composition for treating gout and hyperuricemia |
| CN108403987A (en) * | 2018-05-11 | 2018-08-17 | 刘松松 | One kind preventing antipodagric witloof jasmine tea |
| CN109349384A (en) * | 2018-11-16 | 2019-02-19 | 万顺宝(肇庆)实业有限公司 | It is a kind of to have effects that reduce the miracle fruit compound tea and preparation method thereof of uric acid |
| CN110960638A (en) * | 2019-12-30 | 2020-04-07 | 李刚 | Composition for reducing uric acid and preparation method thereof |
-
2021
- 2021-03-04 CN CN202110237415.0A patent/CN113812614A/en active Pending
- 2021-03-04 CN CN202311312601.1A patent/CN117204560A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113812614A (en) | 2021-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102579912A (en) | Chinese medicinal capsules special for treating acute mastitis and preparation method thereof | |
| CN102406896A (en) | Pharmaceutical composition for treating chronic cholecystitis | |
| CN103555530A (en) | Lily healthcare medicinal liquor | |
| CN117204560A (en) | Functional food for resisting uric acid | |
| CN103977281A (en) | Traditional Chinese medicine composition for treating female endocrine disorders and preparation method thereof | |
| CN102579677B (en) | Chinese medicinal composition for treating brain glioma | |
| CN115282229B (en) | Traditional Chinese medicine composition for treating qi deficiency and blood stasis type coronary heart disease and preparation method thereof | |
| CN116492428A (en) | A Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN112717113B (en) | Traditional Chinese medicine composition for treating allergic rhinitis and paste formula and application thereof | |
| CN104056242A (en) | Traditional Chinese medicine composition for treating acute cholecystitis and preparation method thereof | |
| CN114404517A (en) | Composition for gout and reducing uric acid and application and preparation method thereof | |
| CN102755516B (en) | Traditional Chinese medicine preparation for inhibiting human immunodeficiency virus and preparation method thereof | |
| CN105435131A (en) | Traditional Chinese medicine composition for treating chronic heart failure and preparation method thereof | |
| CN103656459B (en) | A traditional Chinese medicine for treating cough due to deficiency of both lung and spleen | |
| KR102692595B1 (en) | Composition for treating and preventing constipation comprising Angelica gigas extract as an active ingredient | |
| CN110123896B (en) | Pharmaceutical composition for adjuvant treatment of tumor and preparation method thereof | |
| CN107362301A (en) | Fragrant Siberian cocklebur appetizing particle | |
| CN107737250A (en) | A kind of hypertension Chinese medicine composition and preparation method thereof | |
| CN118021913A (en) | Zhuang medicine for treating hemorrhoids and resisting tumors and preparation method thereof | |
| CN105288166A (en) | Traditional Chinese medicine composition for thyroid enlargement and preparation method thereof | |
| CN104606462A (en) | Medicine for conditioning alcoholic fatty liver and preparation method of medicine | |
| CN102755442B (en) | Chinese herbal preparation for adjuvant therapy of AIDS and production method of same | |
| CN113057317A (en) | Split ointment formula suitable for diabetes and high risk group thereof | |
| CN111494556A (en) | A kind of traditional Chinese medicine composition for preventing and treating three high and fatty liver and its preparation and application | |
| CN111821385A (en) | Health-preserving health wine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |